Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 205

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Allogeneic Bone Marrow Transplantation for Therapy-Related Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Long-Term Study of 70 Patients—Report of the French Society of Bone Marrow Transplantation

Yakoub-Agha, I., de La Salmonière, P., Ribaud, P., Sutton, L., Wattel, E., Kuentz, M., Jouet, J.P., Marit, G., Milpied, N., Deconinck, E., Gratecos, N., Leporrier, M., Chabbert, I., Caillot, D., Damaj, G., Dauriac, C., Dreyfus, F., François, S., Molina, L., Tanguy, M.L., Chevret, S., Gluckman, E.·2000·Journal of Clinical Oncology

Abstract

PURPOSE: To identify predictive factors of survival, relapse, and transplantation-related mortality (TRM) among patients with therapy-related myelodysplastic syndrome (t-MDS) or acute leukemia (t-AML) who underwent allogeneic bone marrow transplantation (BMT). PATIENTS AND METHODS: From 1980 to 1998, 70 patients underwent allogeneic BMT for t-MDS (n = 31) or t-AML (n = 39) after prior cytotoxic exposure. Thirty-three patients had received induction-type chemotherapy before BMT. At the time of transplantation, there were 24 patients in complete remission (CR) and 46 with active disease. RESULTS: With a median follow-up of 7.9 years (range, 1.1 to 18.8 years) after BMT, 16 patients are alive, whereas 19 died of relapse, 34 of TRM, and one of relapse of the primary disease. The estimated 2-year overall survival, event-free survival, relapse, and TRM rates were 30% (95% confidence interval [CI], 19% to 40%), 28% (95% CI, 18% to 39%), 42% (95% CI, 26% to 57%), and 49% (95% CI, 36% to 62%), respectively. In multivariable analysis, age greater than 37 years, male sex, positive recipient cytomegalovirus (CMV) serology, absence of CR at BMT, and intensive schedules used for conditioning were associated with poor outcome. CONCLUSION: BMT is an effective treatment for patients with t-MDS or t-AML who have responsive disease and, in particular, who have no poor-risk cytogenetic features. The poor results of the other patients, especially those with active disease at BMT, emphasize the need to delineate indications and perform prospective protocols.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2000.18.5.963

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 205

Metadata

Authors
Yakoub-Agha, I., de La Salmonière, P., Ribaud, P., Sutton, L., Wattel, E., Kuentz, M., Jouet, J. P., Marit, G., Milpied, N., Deconinck, E., Gratecos, N., Leporrier, M., Chabbert, I., Caillot, D., Damaj, G., Dauriac, C., Dreyfus, F., François, S., Molina, L., Tanguy, M. L., Chevret, S., & Gluckman, E.
Venue
Journal of Clinical Oncology
Published
2000-03-01
Volume
18
Issue
5
Pages
963-963
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W1856810180
Cited by
205
References
2
FWCI
5.41
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Allogeneic Bone Marrow Transplantation for Therapy-Related Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Long-Term Study of 70 Patients—Report of the French Society of Bone Marrow Transplantation. https://app.cochat.ai/papers/10.1200/jco.2000.18.5.963
The paper
Yakoub-Agha, I., de La Salmonière, P., Ribaud, P., Sutton, L., Wattel, E., Kuentz, M., Jouet, J. P., Marit, G., Milpied, N., Deconinck, E., Gratecos, N., Leporrier, M., Chabbert, I., Caillot, D., Damaj, G., Dauriac, C., Dreyfus, F., François, S., Molina, L., . . . Gluckman, E. (2000). Allogeneic Bone Marrow Transplantation for Therapy-Related Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Long-Term Study of 70 Patients—Report of the French Society of Bone Marrow Transplantation. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2000.18.5.963

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.